Like a lot of biotechs this is a race to get to market, and...

Like a lot of biotechs this is a race to get to market, and there are other companies trying to do the same, still it's a huge market if you can carve your own little niche:
I guess this would be one of your competitors:


Relief for pain drug company



PAINKILLER company, CeNeS has published more good news about its lead product M6G, which is completing late-stage clinical trials after years of development.

M6G is set to rival morphine, which has long-held the lead in pain relief.

The drug has fewer side-effects, and latest results show patients need significantly less sedation after an operation, making it ideal for day-surgery.

Morphine tends to cause nausea in women, who are more prone than men to suffer in this way, but M6G cuts this right back.

Neil Clark, ceo, said: "It's estimated that at least 277 million units of injectable analgesics were used to treat pain in the US last year.

"The US post-operative pain market is worth $1.7 billion, and we're confident that M6G will establish a strong position globally.